Biotech Market Outlook for Q2 2026
The biotech market outlook for Q2 2026 reflects a sector balancing scientific momentum with disciplined capital allocation. Following a multi-year recalibration in public markets, US biotechnology companies are entering the second quarter with improved financing windows, selective IPO activity, and renewed strategic partnering. However, macroeconomic variables, regulatory scrutiny, and pricing debates continue to shape valuation … Read more